Clinical MDx firm OmniSeq has been an early-access user of the research-use-only assay and is working on validating it to predict checkpoint inhibitor response.
Data for hundreds of breast tumors suggested specific signatures were more closely linked to tumor-infiltrating lymphocyte activity than was mutational load.
The deal will leverage BioNTech's IVAC Mutanome platform, which uses next-generation sequencing to identify targets for personalized mRNA-based vaccines.
